Skip to main content
. 2022 Jan 28;4(1):e210070. doi: 10.1148/rycan.210070

Figure 6:

Clinical PET/CT imaging studies in patients with (A) ovarian and (B) breast cancer. (A) The standardized uptake value (SUV) measurements of 18F fluorthanatrace (18F-FTT) in patients with ovarian cancer (n = 20 women; age range, 22–68 years; median, 60 years) varied greatly, from 2 (background) to 12 (highest). Arrows indicate the site of disease. This is the representation of three images from patients with low, medium, and high uptake. (B) In a follow-up breast cancer trial, four patients (age range, 41–71 years; median age, 52 years) with stage III or IV disease and receiving poly (adenosine diphosphate–ribose) polymerase inhibitor (PARPi) therapy were enrolled. Three of the tumors were triple negative and one was estrogen positive. The initial SUV was moderate, 4.2–6.8, at baseline (left). After 1 week of PARPi treatment, the participants were scanned with 18F-FTT again. The uptake of 18F-FTT was diminished after the PARPi treatment. (Data reproduced from references 16 and 31.) (B reprinted, with permission, from reference 16.)

Clinical PET/CT imaging studies in patients with (A) ovarian and (B) breast cancer. (A) The standardized uptake value (SUV) measurements of 18F fluorthanatrace (18F-FTT) in patients with ovarian cancer (n = 20 women; age range, 22–68 years; median, 60 years) varied greatly, from 2 (background) to 12 (highest). Arrows indicate the site of disease. This is the representation of three images from patients with low, medium, and high uptake. (B) In a follow-up breast cancer trial, four patients (age range, 41–71 years; median age, 52 years) with stage III or IV disease and receiving poly (adenosine diphosphate–ribose) polymerase inhibitor (PARPi) therapy were enrolled. Three of the tumors were triple negative and one was estrogen positive. The initial SUV was moderate, 4.2–6.8, at baseline (left). After 1 week of PARPi treatment, the participants were scanned with 18F-FTT again. The uptake of 18F-FTT was diminished after the PARPi treatment. (Data reproduced from references 16 and 31.) (B reprinted, with permission, from reference 16.)